

Special Issue

Immunization and Immunotherapy against Emerging Infectious Diseases: Current Challenges, Innovative Vaccine Development and Vaccine Adjuvant Technologies

Message from the Guest Editors

Newly emerging and reemerging infectious pathogens, especially the unprecedented viral epidemics and pandemics, have threatened animals and humans. Several interlaced and synergistic factors could accelerate the emergence and spread of these life-threatening pathogens in hosts such as animal and/or human populations. Due to the limited antimicrobial options against emerging and reemerging infectious pathogens and the rapid development of drug-resistant strains following uncontrolled implementation of these medications to infected animals, the vaccination and cell-based immunostimulatory therapies remain pivotal options against these infectious pathogens in both animal and human populations. Therefore, in this issue, we are interested in receiving manuscripts for studies with innovative findings in the following topics:

- Immunization against emerging infectious diseases;
- Immunotherapy against emerging infectious diseases;
- Challenges to current vaccination strategies;
- Innovative vaccine development (new-generation) technologies;
- Novel vaccine adjuvant technologies.

Guest Editors

Dr. Ahmed Mostafa

Center of Scientific Excellence for Influenza Viruses, National Research Centre, 12622 Giza, Egypt

Dr. Mobarak Abu Mraheil

Giessen Institute for Medical Microbiology, Justus-Liebig University, 35392 Giessen, Germany

Deadline for manuscript submissions

closed (31 December 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/153105

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).